EN DE
Watch SDS Optic Spolka Akcyjna discovers, for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SDS Optic Spolka Akcyjna discovers (SDS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SDS Optic Spolka Akcyjna discovers stock PLN 1.80, price PLN 2.90, that is 37.9% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLSDSOP00013

SO SDS Optic Spolka Akcyjna discovers logo Thin data Nov 10, 2026

SDS Optic Spolka Akcyjna discovers

SDS · WAR
Very expensive, weak quality

Our calculation puts a fair price 38% below what the stock costs today.

Fair value 1.80 PLN · Strongly overvalued
Quality 29/100
Weak Growth (revenue 3y −3.9 %/yr in PLN)
High debt
Negative free cash flow
Trails peers (1/8)
Narrow moat 23/100 · thin data
Thin data
Estimate
Watch SDS Optic Spolka Akcyjna discovers, for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

39.50 PLN 2.10 PLN Fair Value 1.80 PLN Mar 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

56‑month range 2.10 PLN – 39.50 PLN · fair‑value band 1.35 PLN – 2.25 PLN · the 2.90 PLN price screens above the 1.80 PLN fair value. As of Nov 10, 2026.

Follow SDS Optic Spolka Akcyjna discovers, in your weekly email

Every Wednesday you see whether SDS Optic Spolka Akcyjna discovers, is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SDS Optic Spolka Akcyjna discovers, develops, produces, and commercializes diagnostics and monitoring tools worldwide. It offers inPROBE, a cancer diagnostics and treatment device that measure the level of active ingredients in cancer tumor cells.

Show moreShow less

The company is also involved in the modeling and designing of package components, such as ferrules, housings, and other devices with flat and conical surface areas.

In addition, it provides contract chemistry, molecular biology, multidisciplinary in vivo diagnostics and monitoring solutions development, comparative studies of biosimilar products, and early-stage in vivo and in vitro diagnostic technologies scale-up and commercialization services, as well as undertakes integrated multiple key-steps pre-clinical discovery projects.

The company was founded in 2013 and is based in Lublin, Poland.

Stock analysis

SDS Optic Spolka Akcyjna discovers (SDS) currently trades at 2.90 PLN, while our estimate is 1.80 PLN, 38% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1.35 PLN (bear) to 2.25 PLN (bull), the price of 2.90 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

SDS Optic Spolka Akcyjna discovers, reported revenue of 753K PLN in FY2025 versus 849K PLN in FY2022, a compound −3.9%/yr. Reported net income was −2.8M PLN in FY2025.

Key figures

Market cap 19.4M PLN (≈ $5.0M) Micro · EPS (TTM) −0.4500 PLN · Return on assets (EBIT) −29.7% (4-year average) · Free cash flow −7.4M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 67% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −38%, SDS screens richer than that median.

Fair Value

Bear 1.35 PLN Fair Value 1.80 PLN Bull 2.25 PLN
Price 2.90 PLN · Downside -37.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 86
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 5
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 29
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SDS screens overvalued: fair value 38% below the price. Compare with Abbott Laboratories, →

Compare SDS Optic Spolka Akcyjna discovers, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −37.9% · Bottom 25%
Profitability
Return on assets −16.7% · Below median
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median
Balance sheet
Debt / equity 8.81× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.16× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs SDS
DexCom, Inc DXCM $79.92 $89.18 +12% vs SDS
Stryker Corporation SYK $324.29 $358.30 +10% vs SDS
STERIS plc STE $257.12 $279.53 +9% vs SDS
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs SDS
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs SDS
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs SDS
Abbott Laboratories, ABT $110.46 $75.28 −32% vs SDS
Medtronic plc MDT $101.59 $65.61 −35% vs SDS
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs SDS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SDS Optic Spolka Akcyjna discovers,: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SDS Optic Spolka Akcyjna discovers, Fair Value". https://www.fairvalue-calculator.com/stock/SDS.WAR

Frequently asked questions

Is SDS Optic Spolka Akcyjna discovers (SDS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1.80 PLN versus a price of 2.90 PLN, about 38% lower (overvalued).
What is the fair value of SDS?
Our estimate for SDS Optic Spolka Akcyjna discovers is 1.80 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 2.90 PLN.
What is the quality score of SDS?
SDS Optic Spolka Akcyjna discovers has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SDS Optic Spolka Akcyjna discovers (SDS)?
Our calculated price target is the estimate of 1.80 PLN (as of Nov 10, 2026). Cautious scenario 1.35 PLN, optimistic scenario 2.25 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SDS Optic Spolka Akcyjna discovers, stock forecast for 2026?
Our estimate puts fair value at 1.80 PLN, about 38% lower versus a price of 2.90 PLN (overvalued). Cautious scenario 1.35 PLN, optimistic scenario 2.25 PLN. The calculation is refreshed regularly with new filings.
What is the intrinsic value of SDS Optic Spolka Akcyjna discovers (SDS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SDS Optic Spolka Akcyjna discovers it is 1.80 PLN per share (as of Nov 10, 2026), against a price of 2.90 PLN.
Is SDS Optic Spolka Akcyjna discovers, stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SDS trades above its calculated fair value: price 2.90 PLN, fair value 1.80 PLN, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SDS?
No. The price is what the market pays today (2.90 PLN); the fair value is what the company's own numbers justify (1.80 PLN). For SDS Optic Spolka Akcyjna discovers the two are 1.10 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is SDS Optic Spolka Akcyjna discovers, worth?
The market values SDS Optic Spolka Akcyjna discovers at about 19.4M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 2.90 PLN; our models calculate a fair value of 1.80 PLN per share.
What do the bullish and bearish scenarios say about SDS?
Our models span a range for SDS Optic Spolka Akcyjna discovers: cautious scenario 1.35 PLN, base 1.80 PLN, optimistic 2.25 PLN per share (as of Nov 10, 2026, price 2.90 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SDS Optic Spolka Akcyjna discovers (SDS)?
Balance-sheet figures for SDS Optic Spolka Akcyjna discovers (as of Nov 10, 2026): debt of 8.81 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is SDS from its 52-week high?
SDS Optic Spolka Akcyjna discovers trades at 2.90 PLN, about 67% below its 52-week high of 8.76 PLN and 4% above the low of 2.80 PLN (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1.80 PLN is for.
Which stocks are comparable to SDS Optic Spolka Akcyjna discovers,?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SDS Optic Spolka Akcyjna discovers, stock attractive at the current price?
The data as of Nov 10, 2026: price 2.90 PLN, calculated fair value 1.80 PLN (−38%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. SDS Optic Spolka Akcyjna discovers itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SDS Optic Spolka Akcyjna discovers (SDS)?
The closing price on Nov 10, 2026 was 2.90 PLN. Our estimate is 1.80 PLN, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SDS Optic Spolka Akcyjna discovers, right now?
The price sits above even our optimistic bull case (2.25 PLN). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of SDS Optic Spolka Akcyjna discovers

How large is the market capitalisation of SDS Optic Spolka Akcyjna discovers (SDS)?
The market capitalisation of SDS Optic Spolka Akcyjna discovers is 19.4M PLN (≈ $5.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of SDS Optic Spolka Akcyjna discovers (SDS)?
Earnings per share at SDS Optic Spolka Akcyjna discovers are −0.4500 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of SDS Optic Spolka Akcyjna discovers (SDS)?
On an EBIT basis the return on assets of SDS Optic Spolka Akcyjna discovers is −29.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does SDS Optic Spolka Akcyjna discovers (SDS) generate?
The free cash flow of SDS Optic Spolka Akcyjna discovers is −7.4M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch SDS Optic Spolka Akcyjna discovers, in the live analysis

One click puts SDS Optic Spolka Akcyjna discovers, on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.